These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16820704)

  • 61. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
    Andrade VA; Gross JL; Maia AL
    Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
    Fukao A; Takamatsu J; Murakami Y; Sakane S; Miyauchi A; Kuma K; Hayashi S; Hanafusa T
    Clin Endocrinol (Oxf); 2003 May; 58(5):550-5. PubMed ID: 12699435
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
    Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Incidence of and Risk Factors for Neonatal Hypothyroidism Among Women with Graves' Disease Treated with Antithyroid Drugs Until Delivery.
    Yoshihara A; Noh JY; Inoue K; Watanabe N; Fukushita M; Matsumoto M; Suzuki N; Suzuki A; Kinoshita A; Yoshimura R; Aida A; Imai H; Hiruma S; Sugino K; Ito K
    Thyroid; 2023 Mar; 33(3):373-379. PubMed ID: 36680759
    [No Abstract]   [Full Text] [Related]  

  • 65. Comparison of Five TSH-Receptor Antibody Assays in Graves' disease: results from an observational pilot study.
    Struja T; Jutzi R; Imahorn N; Kaeslin M; Boesiger F; Kutz A; Mundwiler E; Huber A; Kraenzlin M; Mueller B; Meier C; Bernasconi L; Schuetz P
    BMC Endocr Disord; 2019 Apr; 19(1):38. PubMed ID: 31023276
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 67. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
    Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
    Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil.
    Momotani N; Yamashita R; Makino F; Noh JY; Ishikawa N; Ito K
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):177-81. PubMed ID: 10931098
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW; Liu RT; Tung SC; Chien WY; Lu YC; Chen CH; Kuo MC; Hsieh JR; Wang ST
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Measuring TSH receptor antibody to influence treatment choices in Graves' disease.
    Hesarghatta Shyamasunder A; Abraham P
    Clin Endocrinol (Oxf); 2017 May; 86(5):652-657. PubMed ID: 28295509
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations.
    Foley TP; White C; New A
    J Pediatr; 1987 Mar; 110(3):378-86. PubMed ID: 2880956
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies.
    Stöhr M; Oeverhaus M; Lytton SD; Horstmann M; Zwanziger D; Möller L; Stark A; Führer-Sakel D; Bechrakis N; Berchner-Pfannschmidt U; Banga JP; Philipp S; Eckstein A
    Horm Metab Res; 2021 Apr; 53(4):235-244. PubMed ID: 33618407
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [TBL] [Abstract][Full Text] [Related]  

  • 79. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.